Collection
Targeted Therapy of Rare Tumors
Therapeutic options for less frequent tumor types are often limited. Enhanced genomic studies have identified recurrent aberrations in rarer tumors, leading to research on the use of targeted agents in these indications. This collection curates clinical studies of molecularly targeted drugs for rare cancers.
Articles (11 in this collection)
-
-
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study
Authors (first, second and last of 15)
-
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Authors (first, second and last of 21)
-
Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
Authors (first, second and last of 9)
-
Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
Authors (first, second and last of 8)
-
Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature
Authors (first, second and last of 7)
-
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
Authors (first, second and last of 5)
-
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
Authors (first, second and last of 23)
-
Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm
Authors (first, second and last of 5)
-
Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study
Authors (first, second and last of 8)
-
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study
Authors (first, second and last of 6)
